Access to oncology medicines in EU and OECD countries:
Ensuring equal access to the latest cancer medicines is one of the most pressing challenges facing OECD health systems today. Despite the emergence of new oncology drugs, disparities in patient access-particularly through clinical trials and early access programs-remain a critical issue. Rising cost...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | , |
| Format: | Electronic eBook |
| Language: | English |
| Published: |
Paris
OECD Publishing
2024
|
| Series: | OECD Health Working Papers
no.170 |
| Subjects: | |
| Online Access: | DE-862 DE-863 |
| Summary: | Ensuring equal access to the latest cancer medicines is one of the most pressing challenges facing OECD health systems today. Despite the emergence of new oncology drugs, disparities in patient access-particularly through clinical trials and early access programs-remain a critical issue. Rising costs are also straining even the most affluent healthcare systems, making affordability a concern for all. This working paper examines various aspects of inequalities in access to cancer medicines, covering key stages in a medicine's life cycle, from marketing authorization to reimbursement decisions and uptake in clinical practice. The analysis draws on original findings from the 2023 OECD Policy Survey on Cancer Care Performance. It also explores potential strategies to stimulate competition among oncology medicine producers, which could create significant budget headroom, allowing reinvestment in new cancer medicines that offer substantial clinical benefits to patients. |
| Physical Description: | 1 Online-Ressource (76 Seiten) 21 x 28cm. |
Staff View
MARC
| LEADER | 00000nam a22000002 4500 | ||
|---|---|---|---|
| 001 | ZDB-13-SOC-109257685 | ||
| 003 | DE-627-1 | ||
| 005 | 20241028115317.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 241028s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1787/c263c014-en |2 doi | |
| 035 | |a (DE-627-1)109257685 | ||
| 035 | |a (DE-599)KEP109257685 | ||
| 035 | |a (FR-PaOEC)c263c014-en | ||
| 035 | |a (DE-627-1)109257685 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a I11 |2 jelc | ||
| 084 | |a I13 |2 jelc | ||
| 084 | |a O30 |2 jelc | ||
| 084 | |a L11 |2 jelc | ||
| 084 | |a H51 |2 jelc | ||
| 084 | |a I18 |2 jelc | ||
| 100 | 1 | |a Hofmarcher, Thomas |e VerfasserIn |4 aut | |
| 245 | 1 | 0 | |a Access to oncology medicines in EU and OECD countries |c Thomas, Hofmarcher, Caroline, Berchet and Guillaume, Dedet |
| 264 | 1 | |a Paris |b OECD Publishing |c 2024 | |
| 300 | |a 1 Online-Ressource (76 Seiten) |c 21 x 28cm. | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 490 | 0 | |a OECD Health Working Papers |v no.170 | |
| 520 | |a Ensuring equal access to the latest cancer medicines is one of the most pressing challenges facing OECD health systems today. Despite the emergence of new oncology drugs, disparities in patient access-particularly through clinical trials and early access programs-remain a critical issue. Rising costs are also straining even the most affluent healthcare systems, making affordability a concern for all. This working paper examines various aspects of inequalities in access to cancer medicines, covering key stages in a medicine's life cycle, from marketing authorization to reimbursement decisions and uptake in clinical practice. The analysis draws on original findings from the 2023 OECD Policy Survey on Cancer Care Performance. It also explores potential strategies to stimulate competition among oncology medicine producers, which could create significant budget headroom, allowing reinvestment in new cancer medicines that offer substantial clinical benefits to patients. | ||
| 650 | 4 | |a Social Issues/Migration/Health | |
| 700 | 1 | |a Berchet, Caroline |e MitwirkendeR |4 ctb | |
| 700 | 1 | |a Dedet, Guillaume |e MitwirkendeR |4 ctb | |
| 966 | 4 | 0 | |l DE-862 |p ZDB-13-SOC |q FWS_PDA_SOC |u https://doi.org/10.1787/c263c014-en |m X:OECD |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 966 | 4 | 0 | |l DE-863 |p ZDB-13-SOC |q FWS_PDA_SOC |u https://doi.org/10.1787/c263c014-en |m X:OECD |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 912 | |a ZDB-13-SOC-ebook | ||
| 912 | |a ZDB-13-SOC | ||
| 951 | |a BO | ||
| 912 | |a ZDB-13-SOC | ||
| 049 | |a DE-862 | ||
| 049 | |a DE-863 | ||
Record in the Search Index
| DE-BY-FWS_katkey | ZDB-13-SOC-109257685 |
|---|---|
| _version_ | 1826942494370168832 |
| adam_text | |
| any_adam_object | |
| author | Hofmarcher, Thomas |
| author2 | Berchet, Caroline Dedet, Guillaume |
| author2_role | ctb ctb |
| author2_variant | c b cb g d gd |
| author_facet | Hofmarcher, Thomas Berchet, Caroline Dedet, Guillaume |
| author_role | aut |
| author_sort | Hofmarcher, Thomas |
| author_variant | t h th |
| building | Verbundindex |
| bvnumber | localFWS |
| collection | ZDB-13-SOC-ebook ZDB-13-SOC |
| ctrlnum | (DE-627-1)109257685 (DE-599)KEP109257685 (FR-PaOEC)c263c014-en |
| discipline | Wirtschaftswissenschaften |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02373nam a22004332 4500</leader><controlfield tag="001">ZDB-13-SOC-109257685</controlfield><controlfield tag="003">DE-627-1</controlfield><controlfield tag="005">20241028115317.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">241028s2024 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1787/c263c014-en</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627-1)109257685</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)KEP109257685</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(FR-PaOEC)c263c014-en</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627-1)109257685</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">I11</subfield><subfield code="2">jelc</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">I13</subfield><subfield code="2">jelc</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">O30</subfield><subfield code="2">jelc</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">L11</subfield><subfield code="2">jelc</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">H51</subfield><subfield code="2">jelc</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">I18</subfield><subfield code="2">jelc</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Hofmarcher, Thomas</subfield><subfield code="e">VerfasserIn</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Access to oncology medicines in EU and OECD countries</subfield><subfield code="c">Thomas, Hofmarcher, Caroline, Berchet and Guillaume, Dedet</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Paris</subfield><subfield code="b">OECD Publishing</subfield><subfield code="c">2024</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (76 Seiten)</subfield><subfield code="c">21 x 28cm.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">OECD Health Working Papers</subfield><subfield code="v">no.170</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Ensuring equal access to the latest cancer medicines is one of the most pressing challenges facing OECD health systems today. Despite the emergence of new oncology drugs, disparities in patient access-particularly through clinical trials and early access programs-remain a critical issue. Rising costs are also straining even the most affluent healthcare systems, making affordability a concern for all. This working paper examines various aspects of inequalities in access to cancer medicines, covering key stages in a medicine's life cycle, from marketing authorization to reimbursement decisions and uptake in clinical practice. The analysis draws on original findings from the 2023 OECD Policy Survey on Cancer Care Performance. It also explores potential strategies to stimulate competition among oncology medicine producers, which could create significant budget headroom, allowing reinvestment in new cancer medicines that offer substantial clinical benefits to patients.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Social Issues/Migration/Health</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Berchet, Caroline</subfield><subfield code="e">MitwirkendeR</subfield><subfield code="4">ctb</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Dedet, Guillaume</subfield><subfield code="e">MitwirkendeR</subfield><subfield code="4">ctb</subfield></datafield><datafield tag="966" ind1="4" ind2="0"><subfield code="l">DE-862</subfield><subfield code="p">ZDB-13-SOC</subfield><subfield code="q">FWS_PDA_SOC</subfield><subfield code="u">https://doi.org/10.1787/c263c014-en</subfield><subfield code="m">X:OECD</subfield><subfield code="x">Resolving-System</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="4" ind2="0"><subfield code="l">DE-863</subfield><subfield code="p">ZDB-13-SOC</subfield><subfield code="q">FWS_PDA_SOC</subfield><subfield code="u">https://doi.org/10.1787/c263c014-en</subfield><subfield code="m">X:OECD</subfield><subfield code="x">Resolving-System</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-13-SOC-ebook</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-13-SOC</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">BO</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-13-SOC</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-862</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-863</subfield></datafield></record></collection> |
| id | ZDB-13-SOC-109257685 |
| illustrated | Not Illustrated |
| indexdate | 2025-03-18T14:28:54Z |
| institution | BVB |
| language | English |
| open_access_boolean | |
| owner | DE-862 DE-BY-FWS DE-863 DE-BY-FWS |
| owner_facet | DE-862 DE-BY-FWS DE-863 DE-BY-FWS |
| physical | 1 Online-Ressource (76 Seiten) 21 x 28cm. |
| psigel | ZDB-13-SOC FWS_PDA_SOC ZDB-13-SOC-ebook ZDB-13-SOC |
| publishDate | 2024 |
| publishDateSearch | 2024 |
| publishDateSort | 2024 |
| publisher | OECD Publishing |
| record_format | marc |
| series2 | OECD Health Working Papers |
| spelling | Hofmarcher, Thomas VerfasserIn aut Access to oncology medicines in EU and OECD countries Thomas, Hofmarcher, Caroline, Berchet and Guillaume, Dedet Paris OECD Publishing 2024 1 Online-Ressource (76 Seiten) 21 x 28cm. Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier OECD Health Working Papers no.170 Ensuring equal access to the latest cancer medicines is one of the most pressing challenges facing OECD health systems today. Despite the emergence of new oncology drugs, disparities in patient access-particularly through clinical trials and early access programs-remain a critical issue. Rising costs are also straining even the most affluent healthcare systems, making affordability a concern for all. This working paper examines various aspects of inequalities in access to cancer medicines, covering key stages in a medicine's life cycle, from marketing authorization to reimbursement decisions and uptake in clinical practice. The analysis draws on original findings from the 2023 OECD Policy Survey on Cancer Care Performance. It also explores potential strategies to stimulate competition among oncology medicine producers, which could create significant budget headroom, allowing reinvestment in new cancer medicines that offer substantial clinical benefits to patients. Social Issues/Migration/Health Berchet, Caroline MitwirkendeR ctb Dedet, Guillaume MitwirkendeR ctb |
| spellingShingle | Hofmarcher, Thomas Access to oncology medicines in EU and OECD countries Social Issues/Migration/Health |
| title | Access to oncology medicines in EU and OECD countries |
| title_auth | Access to oncology medicines in EU and OECD countries |
| title_exact_search | Access to oncology medicines in EU and OECD countries |
| title_full | Access to oncology medicines in EU and OECD countries Thomas, Hofmarcher, Caroline, Berchet and Guillaume, Dedet |
| title_fullStr | Access to oncology medicines in EU and OECD countries Thomas, Hofmarcher, Caroline, Berchet and Guillaume, Dedet |
| title_full_unstemmed | Access to oncology medicines in EU and OECD countries Thomas, Hofmarcher, Caroline, Berchet and Guillaume, Dedet |
| title_short | Access to oncology medicines in EU and OECD countries |
| title_sort | access to oncology medicines in eu and oecd countries |
| topic | Social Issues/Migration/Health |
| topic_facet | Social Issues/Migration/Health |
| work_keys_str_mv | AT hofmarcherthomas accesstooncologymedicinesineuandoecdcountries AT berchetcaroline accesstooncologymedicinesineuandoecdcountries AT dedetguillaume accesstooncologymedicinesineuandoecdcountries |